AbbVie Inc.
ABBV
$210.06
-$1.49-0.70%
| Weiss Ratings | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | C+ | |||
| Rating Factors | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Good | |||
| Growth Index | Weak | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.05 | |||
| Price History | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.90% | |||
| 30-Day Total Return | 24.15% | |||
| 60-Day Total Return | 20.35% | |||
| 90-Day Total Return | 12.85% | |||
| Year to Date Total Return | 18.16% | |||
| 1-Year Total Return | 20.23% | |||
| 2-Year Total Return | 45.88% | |||
| 3-Year Total Return | 57.34% | |||
| 5-Year Total Return | 191.90% | |||
| 52-Week High % Change | -1.91% | |||
| 52-Week Low % Change | 37.74% | |||
| Price | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $215.66 | |||
| 52-Week Low Price | $153.58 | |||
| 52-Week Low Price (Date) | May 30, 2024 | |||
| 52-Week High Price (Date) | Mar 04, 2025 | |||
| Valuation | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 373.44B | |||
| Enterprise Value | 435.95B | |||
| Price/Earnings (TTM) | 88.31 | |||
| Earnings Per Share (TTM) | 2.40 | |||
| Earnings Per Share Growth | -12.11% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 6.64 | |||
| Price/Book (Q) | 112.31 | |||
| Enterprise Value/Revenue (TTM) | 7.74 | |||
| Price | $210.06 | |||
| Enterprise Value/EBITDA (TTM) | 16.72 | |||
| Enterprise Value/EBIT | 24.64 | |||
| Market Cap Category | Mega Cap | |||
| Dividends and Shares | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.77B | |||
| Dividend Yield | 2.97% | |||
| Div. Per Share (Most Recent) | $1.64 | |||
| Dividend Per Share (TTM) | $6.29 | |||
| Payout Ratio (TTM) | 257.71% | |||
| Dividend Per Share (Most Recent) | $1.64 | |||
| Company Info | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 847 932 7900 | |||
| Address | 1 North Waukegan Road North Chicago, IL 60064-6400 | |||
| Website | www.abbvie.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 31.40% | |||
| Profit Margin | 7.59% | |||
| Management Effectiveness | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 8.19% | |||
| Return on Equity | 62.29% | |||
| Income Statement | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 56.33B | |||
| Total Revenue (TTM) | 56.33B | |||
| Revenue Per Share | $31.85 | |||
| Gross Profit (TTM) | 39.48B | |||
| EBITDA (TTM) | 26.08B | |||
| EBIT (TTM) | 17.69B | |||
| Net Income (TTM) | 4.28B | |||
| Net Income Avl. to Common (TTM) | 4.28B | |||
| Total Revenue Growth (Q YOY) | 5.60% | |||
| Earnings Growth (Q YOY) | -102.79% | |||
| EPS Diluted (TTM) | 2.40 | |||
| EPS Diluted Growth (Q YOY) | -104.09% | |||
| Balance Sheet | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.56B | |||
| Cash Per Share (Q) | $3.14 | |||
| Total Current Assets (Q) | 25.58B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 3.36B | |||
| Current Ratio (Q) | 0.660 | |||
| Book Value Per Share (Q) | $1.88 | |||
| Total Assets (Q) | 135.16B | |||
| Total Current Liabilities (Q) | 38.75B | |||
| Total Debt (Q) | 68.02B | |||
| Total Liabilities (Q) | 131.80B | |||
| Total Common Equity (Q) | 3.33B | |||
| Cash Flow | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -20.82B | |||
| Cash from Financing (TTM) | -5.21B | |||
| Net Change in Cash (TTM) | -7.29B | |||
| Levered Free Cash Flow (TTM) | 19.58B | |||
| Cash from Operations (TTM) | 18.81B | |||
